In this section you will be introduced to the CUPISCO study. This clinical trial aims to determine the efficacy and safety of targeted therapies and cancer immunotherapies for patients with a subset of CUP syndrome. The selection of therapies is based on results from comprehensive genomic profiling.
Can we improve outcomes in CUP?
So far, data from standard chemotherapy-based clinical trials report median survival times of around one year or less. However, there are options for innovative new clinical trials that explore how to improve outcomes for patients today and in future.1,2
1. Fizazi K et al. Ann Oncol 2015; 26 (suppl 5): v133–8.
2. Hainsworth JD and Greco FA. American Society of Clinical Oncology Educational Book 38 (May 23, 2018) 20–5.